New Data From iRhythm Reinforce the Utility of Long-Term Ambulatory Cardiac Monitoring for Increased Diagnostic Yield and Improved Diagnostic Accuracy of Actionable Arrhythmias
These new data reinforce the body of clinical evidence that long-term ambulatory cardiac monitoring of up to 14 days with Zio® XT increases diagnostic yield and improves diagnostic accuracy of ventricular arrhythmias across a wide range of patient populations.
- These new data reinforce the body of clinical evidence that long-term ambulatory cardiac monitoring of up to 14 days with Zio® XT increases diagnostic yield and improves diagnostic accuracy of ventricular arrhythmias across a wide range of patient populations.
- Early detection and diagnosis are crucial to treating these arrhythmias and preventing adverse health outcomes.
- At least seven days of continuous ambulatory ECG monitoring, performed by the Zio service, was necessary to achieve >95% accuracy in burden categorization.
- In this randomized, placebo-controlled, crossover trial of 41 patients that received Zio XT ambulatory ECG monitoring for seven days, Flecainide significantly reduced PVC burden.